SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 12, 2006
Date of Report (Date of earliest event reported)
NPS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
|(Commission File Number)|| |
383 Colorow Drive
Salt Lake City, Utah 84108
(Address of principal executive offices)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 1.01 Entry into a Material Definitive Agreement.
The Board of Directors of NPS Pharmaceuticals has reduced the annual nonretainer equity portion of nonemployee director compensation by fifty percent (50%) from an annualized equity award target value of $125,000 per director per year to $62,500 per director per year. The annualized equity award target is paid on a quarterly basis and the reduction is applicable to quarterly payments beginning July 15, 2006. All other elements of nonemployee director compensation continue as previously reported in the Companys Proxy Statement for its 2006 Annual Meeting of Stockholders.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 15, 2006
|NPS PHARMACEUTICALS, INC.|
/s/ KEVIN J. ONTIVEROS
Kevin J. Ontiveros,
Vice President, Corporate Law and
Assistant Corporate Secretary